ProKidney Corp. (PROK) - Total Assets
Based on the latest financial reports, ProKidney Corp. (PROK) holds total assets worth $335.57 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore how well can ProKidney Corp. service its debt to assess how comfortably operating cash covers total debt obligations.
ProKidney Corp. - Total Assets Trend (2019–2025)
This chart illustrates how ProKidney Corp.'s total assets have evolved over time, based on quarterly financial data. See ProKidney Corp. (PROK) net assets for net asset value and shareholders' equity analysis.
ProKidney Corp. - Asset Composition Analysis
Current Asset Composition (December 2025)
ProKidney Corp.'s total assets of $335.57 Million consist of 83.6% current assets and 16.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 32.3% |
| Accounts Receivable | $1.13 Million | 0.3% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how ProKidney Corp.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see PROK market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ProKidney Corp.'s current assets represent 83.6% of total assets in 2025, an increase from 78.7% in 2019.
- Cash Position: Cash and equivalents constituted 32.3% of total assets in 2025, down from 77.7% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 4.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 0.3% of total assets.
ProKidney Corp. Competitors by Total Assets
Key competitors of ProKidney Corp. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
ALTEOGEN Inc
KQ:196170
|
Korea | ₩729.47 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $440.10 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Galapagos N.V.
AS:GLPG
|
Netherlands | €3.37 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
ProKidney Corp. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 9.13 | 10.93 | 863.94 |
| Quick Ratio | 9.13 | 10.93 | 863.94 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $249.94 Million | $359.67 Million | $4.57 Million |
ProKidney Corp. - Advanced Valuation Insights
This section examines the relationship between ProKidney Corp.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 97.15 |
| Latest Market Cap to Assets Ratio | 0.65 |
| Asset Growth Rate (YoY) | -23.9% |
| Total Assets | $335.57 Million |
| Market Capitalization | $218.66 Million USD |
Valuation Analysis
Below Book Valuation: The market values ProKidney Corp.'s assets below their book value (0.65x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: ProKidney Corp.'s assets decreased by 23.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for ProKidney Corp. (2019–2025)
The table below shows the annual total assets of ProKidney Corp. from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $335.57 Million | -23.92% |
| 2024-12-31 | $441.07 Million | +4.88% |
| 2023-12-31 | $420.55 Million | -18.81% |
| 2022-12-31 | $518.00 Million | +1185.41% |
| 2021-12-31 | $40.30 Million | +141.31% |
| 2020-12-31 | $16.70 Million | -14.83% |
| 2019-12-31 | $19.61 Million | -- |
About ProKidney Corp.
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the devel… Read more